DETECTION OF CARBAPENEMASE-PRODUCING CARBAPENEM-RESISTANT IN BLOOD CULTURE ISOLATES BY MCIM AND ECIM AND ITS SUSCEPTIBILITY TO TIGECYCLINE AND MINOCYCLINE

pushpa kachari; Anuradha K; Ravindranath C

doi:10.22159/ajpcr.2023.v16i8.47629

Authors

pushpa kachari Department of Microbiology, Mysuru Medical College and Research Institute, Mysuru, Karnataka, India. https://orcid.org/0009-0006-2921-0804
Anuradha K Department of Microbiology, Mysuru Medical College and Research Institute, Mysuru, Karnataka, India. https://orcid.org/0000-0002-5681-1529
Ravindranath C Department of Microbiology, Mysuru Medical College and Research Institute, Mysuru, Karnataka, India. https://orcid.org/0000-0003-3481-0944

DOI:

https://doi.org/10.22159/ajpcr.2023.v16i8.47629

Keywords:

Carbapenem resistant Enterobacterales, Modified carbapenem inactivation method, EDTA-carbapenem inactivation method

Abstract

Objective: In this study, we aimed to detect different Carbapenemase-producing carbapenem-resistant Enterobacterales (CREs) in blood isolates by phenotypic, modified carbapenem inactivation methods (mCIM) and amp; EDTA-carbapenem inactivation methods (eCIM), and also to study the susceptibility of these CREs toward Tigecycline and Minocycline.

Methods: This prospective study included 100 non-duplicate Enterobacterales organisms isolated from 250 blood samples positive for Enterobacterales that showed resistance to carbapenem (Imipenem). The isolates were identified by conventional routine biochemical tests. CRE isolates were screened for Carbapenemase production by the Clinical and Laboratory Standards Institute (CLSI)-recommended, mCIM and eCIM for evidence of the production of matello-beta-lactamase. Antimicrobial susceptibility for Tigecycline and Minocycline drugs was tested by the disk diffusion method on Mueller–Hinton agar according to CLSI guidelines, and susceptibility patterns were recorded. Clinical diagnosis data were collected from the requisition forms sent to our laboratory during test procedures.

Results: Out of 100 (40%) CRE isolates tested for mCIM, 34 samples showed positive results for the Carbapenemase enzyme. Among the mCIM-positive isolates, Klebsiella spp. showed the highest prevalence of 58.8% (20/34). While among mCIM-positive isolates (22/34), 64.7% were positive for eCIM (Matello beta-lactamase producer). Maximum samples had been received from the NICU ward from patients diagnosed with early-onset sepsis; 41.2% of these were Carbapenemase-producing Enterobacterales. Among CRE isolates, 86 isolates were susceptible to Tigecycline and 24 isolates were susceptible to Minocycline. 70 CRE isolates were susceptible to Tigecycline but resistant to minocycline, and all CRE isolates resistant to Tigecycline were not susceptible to Minocycline.

Downloads

Download data is not yet available.

References

Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011;17:1791-8. doi: 10.3201/eid1710.110655, PMID 22000347 Pierce VM, Simner PJ, Lonsway DR, Roe-Carpenter DE, Johnson JK, Brasso WB, et al. Modified carbapenem inactivation method for phenotypic detection of carbapenemase production among Enterobacteriaceae. J Clin Microbiol 2017;55:2321-33. doi: 10.1128/JCM.00193-17, PMID 28381609

Centers for Disease Control and Prevention (CDC). Vital signs: Carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep 2013;62:165-70. PMID 23466435

Available from: https://arpsp.cdc.gov/profile/arln/cre

Available from: https://www.cdc.gov/hai/organisms/cre/index.html

Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard. 12th ed. CLSI Document M02-A12. Wayne, PA: Clinical and Laboratory Standards Institute; 2015.

Yamada K, Kashiwa M, Arai K, Nagano N, Saito R. Comparison of the modified-hodge test, carba NP test, and carbapenem inactivation method as screening methods for carbapenemase-producing Enterobacteriaceae. J Microbiol Methods 2016;128:48-51. doi: 10.1016/j.mimet.2016.06.019, PMID 27329263

Petit M, Caméléna F, Cointe A, Poncin T, Merimèche M, Bonacorsi S, et al. Rapid detection and characterization of carbapenemases in Enterobacterales with a new modified carbapenem inactivation method, mCIMplus. J Clin Microbiol 2020;58:e01370-20. doi: 10.1128/ JCM.01370-20, PMID 32878954

Simner PJ, Johnson JK, Brasso WB, Anderson K, Lonsway DR, Pierce VM, et al. Multicenter evaluation of the modified carbapenem inactivation method and the Carba NP for detection of carbapenemase-producing Pseudomonas aeruginosa and Acinetobacter baumannii. J Clin Microbiol 2018;56:e01369-17. doi: 10.1128/JCM.01369-17

Sfeir MM, Hayden JA, Fauntleroy KA, Mazur C, Johnson JK, Simner PJ, et al. EDTA-modified carbapenem inactivation method: A phenotypic method for detecting metallo-β-lactamase-producing Enterobacteriaceae. J Clin Microbiol 2019;57:e01757-18. doi: 10.1128/JCM.01757-18, PMID 30867235

Aguirre-Quiñonero A, Cano ME, Gamal D, Calvo J, Martínez- Martínez L. Evaluation of the carbapenem inactivation method (CIM) for detecting carbapenemase activity in enterobacteria. Diagn Microbiol Infect Dis 2017;88:214-8. doi: 10.1016/j.diagmicrobio.2017.03.009, PMID 28476242

Gauthier L, Dortet L, Cotellon G, Creton E, Cuzon G, Ponties V, et al. Diversity of carbapenemase-producing Escherichia coli isolates in France in 2012-2013. Antimicrob Agents Chemother 2018;62:e00266- 18. doi: 10.1128/AAC.00266-18, PMID 29866863

Grundmann H, Glasner C, Albiger B, Aanensen DM, Tomlinson CT, Andrasević AT, et al. Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): A prospective, multinational study. Lancet Infect Dis 2017;17:153-63. doi: 10.1016/S1473-3099(16)30257-2, PMID 27866944

Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, et al. Comparative review of the carbapenems. Drugs 2007;67:1027-52. doi: 10.2165/00003495-200767070-00006, PMID 17488146

Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: A molecular, biological, and epidemiological study. Lancet Infect Dis 2010;10:597-602. doi: 10.1016/S1473-3099(10)70143-2, PMID 20705517

Mukherjee S, Mitra S, Dutta S, Basu S. Neonatal sepsis: The impact of carbapenem-resistant and hypervirulent Klebsiella pneumoniae. Front Med (Lausanne) 2021;8:634349. doi: 10.3389/fmed.2021.634349, PMID 34179032

ICMR Reports. Antimicrobial Resistance Research and Surveillance Network Jan 2020 to December 2020 Division of Epidemiology and Communicable Diseases.

Bajaj A, Mishra B, Loomba PS, Thakur A, Sharma A, Rathod PG, et al. Tigecycline susceptibility of carbapenem resistant Enterobacteriaceae and Acinetobacter spp. isolates from respiratory tract: A tertiary care center study. J Krishna Inst Med Sci Univ 2020;9:1-7.

Pawar SK, Mohite ST, Shinde RV, Patil SR, Karande GS. Carbapenem-resistant Enterobacteriaceae: Prevalence and bacteriological profile in a tertiary teaching hospital from rural western India. Indian J Microbiol Res 2020;5:342-7. doi: 10.18231/2394-5478.2018.0072

Thomas R, Ondongo-Ezhet C, Motsoaledi M, Sharland M, Clements M, Velaphi S. Incidence and all-cause mortality rates in neonates infected with carbapenem resistant organisms. Front Trop Dis 2022;3:832011.

Yin L, He L, Miao J, Yang W, Wang X, Ma J, et al. Carbapenem-resistant Enterobacterales colonization and subsequent infection in a neonatal intensive care unit in Shanghai, China. Infect Prev Pract 2021;3:100147. doi: 10.1016/j.infpip.2021.100147, PMID 34647006, PMCID PMC8498732

Bushnell G, Mitrani-Gold F, Mundy LM. Emergence of New Delhi metallo-β- lactamase Type 1-producing Enterobacteriaceae and non-Enterobacteriaceae: Global case detection and bacterial surveillance. Int J Infect Dis 2013;17:e325- 33. doi: 10.1016/j.ijid.2012.11.025, PMID 23332300

Han R, Shi Q, Wu S, Yin D, Peng M, Dong D, et al. Dissemination of carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) among carbapenem-resistant Enterobacteriaceae isolated from adult and children patients in China. Front Cell Infect Microbiol 2020;10:314. doi: 10.3389/fcimb.2020.00314, PMID 32719751

Giammanco A, Calà C, Fasciana T, Dowzicky MJ. Global assessment of the activity of tigecycline against multidrug-resistant Gram-negative pathogens between 2004 and 2014 as part of the tigecycline evaluation and surveillance trial. mSphere 2017;2:e00310-16. doi: 10.1128/ mSphere.00310-16, PMID 28124025

Garrison MW, Mutters R, Dowzicky MJ. In vitro activity of tigecycline and comparator agents against a global collection of gram-negative and gram-positive organisms: Tigecycline evaluation and surveillance trial 2004 to 2007. Diagn Microbiol Infect Dis 2009;65:288-99. doi: 10.1016/j.diagmicrobio.2009.07.010, PMID 19733459